Sensitivity to Intravenous Nicotine: Genetic Moderators

Conditions

Influence of OPRM1 A118G Status on Subjective Responses to IV Nicotine.

What is the purpose of this trial?

To determine if the mu opioid receptor gene (OPRM1) A118G polymorphism moderates the subjective-rewarding effects of intravenous (IV) nicotine in male and female smokers. The subjective effects of nicotine will be measured with a Drug Effects Questionnaire, including the ratings of "good effects" and "drug liking". We hypothesize that smokers with the AG/GG genotype for the OPRM1 A118G will have attenuated subjective-rewarding effects from IV nicotine when compared to those with AA genotype.



Participation Guidelines

Age:
18 Years - 50 Years
Gender:
Both

Click here for detailed information about who can participate in this trial.


Sponsor:
National Institute on Drug Abuse (NIDA)
Yale University
Dates:
June 2009
Last Updated:
December 11, 2013
Study HIC#:
0905005103

Clinicaltrials.gov ID: NCT00969137